HormoneStacks

Evidence comparison

CJC-1295 vs Ipamorelin: Mechanism and Evidence

A medically reviewed comparison of CJC-1295 and ipamorelin, including their different receptor actions, research status, and safety questions.

Written by

HormoneStacks Editorial Team

Health & Wellness Writers

Published 2026-08-21

Medically Reviewed

Dr. Joe S. Lancaster, MD

Board-Certified OB-GYN, Hormone & Longevity Specialist — University of Texas

Reviewed 2026-08-21

Quick answer

CJC-1295 is a growth-hormone-releasing hormone analog, while ipamorelin is a growth-hormone secretagogue that acts at the ghrelin receptor. They are sometimes discussed together because their mechanisms may be complementary, but both require careful medical review and neither should be treated as a proven anti-aging therapy.

Key takeaways

  • They act through different growth-hormone signaling pathways.
  • Research or compounded status does not establish clinical efficacy.
  • Metabolic and sleep-related risks require clinician oversight.

Different signaling pathways

CJC-1295 is discussed as a GHRH analog; ipamorelin is discussed as a selective growth-hormone secretagogue. Their labels and formulations can vary, especially in research and compounded settings.

Evidence limits

Evidence for many non-approved peptide formulations is limited, formulation-dependent, and not equivalent to evidence for an approved medicine. Claims about body composition, recovery, or longevity should be treated cautiously.

Clinical questions

Before considering any growth-hormone pathway intervention, review glucose regulation, edema, sleep-disordered breathing, cancer history, medications, and the reason for treatment with a clinician.

Frequently asked questions

Are CJC-1295 and ipamorelin FDA approved?

Many products marketed under these names are not FDA-approved for general anti-aging or body-composition use. Confirm the exact product and indication with a clinician and pharmacist.

Sources and limitations

This educational page is not medical advice and does not replace an examination or individualized treatment plan. Review the underlying evidence and discuss decisions with a qualified clinician.